Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 14/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 9/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 7/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.37 |
| ▸ | FLT1 | P17948 | 5/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | KIF5B | P33176 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30140098 | 1.00 | EPHA2 (0.41) | EPHA2EGFRKDRMKNK2EPHB4 | |
| SCHEMBL30140390 | 1.00 | EPHA2 (0.41) | EPHA2EGFRKDRMKNK2EPHB4 | |
| SCHEMBL30140065 | 0.98 | EPHA2 (0.41) | EPHA2EGFRKDRMKNK2EPHB4 | |
| SCHEMBL30140177 | 0.98 | EPHA2 (0.41) | EPHA2EGFRKDRMKNK2EPHB4 | |
| SCHEMBL30140289 | 0.96 | EPHA2 (0.43) | EPHA2KDRMKNK2EPHB4ERBB2 | |
| SCHEMBL30140291 | 0.96 | EPHA2 (0.43) | EPHA2KDRMKNK2EPHB4ERBB2 | |
| SCHEMBL30140102 | 0.93 | EPHA2 (0.40) | EPHA2EGFRKDRMKNK2EPHB4 | |
| SCHEMBL30140250 | 0.93 | EPHA2 (0.40) | EPHA2EGFRKDRMKNK2EPHB4 | |
| SCHEMBL30140062 | 0.88 | EGFR (0.42) | EPHA2EGFRKDRMKNK2EPHB4 | |
| SCHEMBL30140443 | 0.88 | EGFR (0.41) | EPHA2EGFRKDRMKNK2EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022266426-A1 | 6-(HETEROCYCLOALKYL-OXY)-QUINAZOLINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |